HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Therapeutic effect of Y-27632 on chronic allograft nephropathy in rats.

AbstractBACKGROUND:
Chronic allograft nephropathy (CAN) is a major cause of late allograft loss. Recent evidences suggest that Rho and its downstream effector ROCK may be greatly involved in the progression of renal fibrosis. Inhibition of Rho/ROCK pathway might interact with the inflammatory process in the renal interstitium, and antagonize the process of epithelial-to-mesenchymal transition (EMT). We hypothesized that Y-27632 could inhibit the chronic inflammatory process and prevent the progression of CAN.
MATERIALS AND METHODS:
Fisher (F344) kidneys were orthotopically transplanted into Lewis rat recipients. Lewis to Lewis rat kidney transplantation was served as the syngeneic control (Syn group). Allograft recipients were randomized and treated with either cyclosporine A alone (Allo group), or in combination with Y-27632 (30 mg/kg body weight/d intragastric, Y-27632 group). Renal function and urine protein excretion levels of the rats were analyzed. Animals were sacrificed 12 wk post-transplantation for histological and immunohistochemical studies, as well as analysis of the expression levels of chemokines, transforming growth factor (TGF-beta) 1 and alpha smooth muscle actin (alpha-SMA).
RESULTS:
Renal function deteriorated progressively in the Allo group, and there was typical CAN morphology in the kidneys. However, Y-27632-treatment significantly prevented the deterioration of graft function, lessened the level of urine protein excretion, and preserved the renal structure. Attenuation of ED1 positive mononuclear cell infiltration and amelioration of tubulointerstitial fibrosis were achieved by Y-27632 intervention. This was associated with down-regulation of the expression of tubular monocyte chemoattractant protein-1, RANTES (regulated upon expression normal T cell expressed and secreted), and phosphorylated NF-kappaB (which was a marker for activation). Profibrotic protein (TGF-beta1) and alpha-SMA, a marker of EMT, were significantly down-regulated by Y-27632 treatment as well.
CONCLUSIONS:
The Rho/ROCK pathway plays an important role in the progression of CAN, and specific inhibition of Rho activity by Y-27632 showed favorable effects on blocking renal interstitial inflammation and fibrosis, thus efficiently retarding the development of CAN, which might provide us with a novel strategy to improve long-term renal graft survival.
AuthorsMin Liu, Min Gu, Yichao Wu, Pengcheng Zhu, Wei Zhang, Changjun Yin, Wei J Zhang
JournalThe Journal of surgical research (J Surg Res) Vol. 157 Issue 1 Pg. e117-27 (Nov 2009) ISSN: 1095-8673 [Electronic] United States
PMID19589538 (Publication Type: Journal Article)
Chemical References
  • Actins
  • Amides
  • Ccl2 protein, rat
  • Chemokine CCL2
  • Chemokine CCL5
  • Enzyme Inhibitors
  • NF-kappa B
  • Pyridines
  • Transforming Growth Factor beta1
  • Y 27632
  • rho-Associated Kinases
Topics
  • Actins (metabolism)
  • Amides (chemistry, pharmacology)
  • Animals
  • Chemokine CCL2 (metabolism)
  • Chemokine CCL5 (metabolism)
  • Chronic Disease
  • Delayed Graft Function (drug therapy, metabolism, pathology)
  • Enzyme Inhibitors (chemistry, pharmacology)
  • Fibrosis
  • Kidney Transplantation
  • Male
  • NF-kappa B (metabolism)
  • Nephritis (drug therapy, metabolism, pathology)
  • Pyridines (chemistry, pharmacology)
  • Rats
  • Rats, Inbred F344
  • Rats, Inbred Lew
  • Transforming Growth Factor beta1 (metabolism)
  • Transplantation, Homologous
  • rho-Associated Kinases (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: